Fig. 2: Cost-effectiveness acceptability curves for vaccination strategies 2xMass18–50 and 2xMassAdultHIV+.
2xMass18–50—two mass campaigns for people aged 18–50; 2xMassAdultHIV+—two mass campaigns for all adults living with HIV.
Fig. 2: Cost-effectiveness acceptability curves for vaccination strategies 2xMass18–50 and 2xMassAdultHIV+. | npj Vaccines
